

Targeting gene editing in pluripotent stem cells: X-SCID disease now in a dish

Jamal Alzubi, PhD

Institute for Cell & Gene Therapy

Freiburg, Germany

Outline

Immune system

- Intact vs. diseased immune system
- T cells function, Why they are important?
- T cells development in human and in cell culture
- Impaired T cells development (X-SCID, X-linked severe combined immunodeficiency)

Designer nucleases

- Types and mode of action
- Tools for gene editing


Pluripotent stem cells (PSCs)

- Types and potential
- Gene editing in PSCs
- Genetic screen for corrected cells
- Differentiation of PSCs to mature effector T cells

Conclusions and perspectives


Immune system

T cell function




Immune system

T cell development




Immune system

visualization of T cell development



Fluorescence-Activated Cell Sorting

FACS




CD, cluster of differentiation



Impaired T cell development

primary immune deficiency

Healthy



Patient




How to correct this mutation?


Designer nucleases

mode of action


Zinc Finger Nuclease (ZFN)




1:3 code
1 ZF \approx 3 bp



Transcription Activator-Like Effector Nucleases (TALEN)




1:1 code
1 repeat = 1 bp



Designer nucleases


tools for gene editing



Pluripotent stem cells

types & potential

Embryonic stem cells, ESCs




Limitations:

- Ethical concerns
- Immune rejection

- 1) Proof of concept for gene therapy
- 2) Disease modeling
- 3) Regenerative medicine applications

Pluripotent stem cells

gene therapy



Hematopoietic stem cells correction

- Proof of concept

Genovese P, et al. 2014. Nature.

- HSCs are hard to culture
- HDR is low in these cells


Pluripotent stem cells correction

- Disease modelling
- Regenerative medicine application

- Efficient differentiation protocols


Pluripotent stem cells

gene editing




Gene editing

Genetic screen




**Successful genetic
correction
GT: 4 out of 100**

in-out PCR




Gene editing

disease model of immunodeficiency



(HDR) (Accurate)





- 1 Proof of concept for gene therapy
- 2 Disease modeling
- 3 Outlook
Regenerative medicine applications ?

Pluripotent stem cells

differentiation



Hematopoietic stem cells generation






Comparable levels of hematopoietic stem cells from both uncorrected and corrected clones

Pluripotent stem cells

differentiation to T cells






restoration of T-cell differentiation
X-SCID disease in a dish




Pluripotent stem cells

maturation of T cells



T cells can mature in a dish to effector T cells

Conclusion & perspectives



Technology platform development

- Designer nuclease can correct pluripotent stem cells of an immunodeficiency (**X-SCID**).

Effector T cells can be generated from PSCs

- X-SCID disease model in a dish

Transplantation of effector T cells to mice

- Check functionality and side effects

Transplantation of effector T cells to human?

- Stabilize the immune system and cure patients

**Institute of Child
Health**
Adrian Thrasher
Celeste Pallant

Toni Cathomen
Christien Bednarski
Laura Mosti
Nicola Bundschuh
Nils Craig-Muller
Viviane Dettmer
Simone Haas
Ruba Hammad
Markus Hildenbeutel
Beate vom Hövel
Valentina Pennucci
Christine Reichenbach
Giandomenico Turchiano

Tatjana Cornu
Marianna Romito
Petra Scheliga-
Marschner
Ilona Skatulla

Claudio Mussolino
Melina el Gaz
Saskia König
Tafadzwa Mlambo
Maximilian Müller

project funded by



Bundesministerium
für Bildung
und Forschung